Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study.
ADAMTS13
Atrial fibrillation
Fibrinogen
Immunothrombosis
NETs
Von Willebrand factor
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
14
06
2021
accepted:
03
09
2021
pubmed:
25
9
2021
medline:
15
2
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia. The etiology underlying AF is still largely unknown. At the intersection of the innate immune system and hemostasis, immunothrombosis may be a possible cause of atrial remodeling, and therefore be an underlying cause of AF. From 1990 to 2014, we followed participants aged 55 and over, free from AF at inclusion. Immunothrombosis factors fibrinogen, von Willebrand factor, ADAMTS13, and neutrophil extracellular traps (NETs) levels were measured at baseline. Participants were followed until either onset of AF, loss-to-follow-up, or reaching the end-date of 01-01-2014. Cox proportional hazard modelling was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for cardiovascular risk factors. We followed 6174 participants (mean age 69.1 years, 57% women) for a median follow-up time of 12.8 years. 364 men (13.7%, incidence rate 13.0/1000 person-years) and 365 women (10.4%, incidence rate 8.9/1000 person-years) developed AF. We found no significant association between markers of immunothrombosis and new-onset AF after adjusting for cardiovascular risk factors [HR 1.00 (95% CI 0.93-1.08) for fibrinogen, 1.04 (0.97-1.12) for von Willebrand factor, 1.00 (1.00-1.01) for ADAMTS13, and 1.01 (0.94-1.09) for NETs]. In addition, we found no differences in associations between men and women. We found no associations between markers of immunothrombosis and new-onset AF in the general population. Inflammation and immunothrombosis may be associated with AF through other cardiovascular risk factors or predisposing conditions of AF. Our findings challenge the added value of biomarkers in AF risk prediction.
Sections du résumé
BACKGROUND
BACKGROUND
Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia. The etiology underlying AF is still largely unknown. At the intersection of the innate immune system and hemostasis, immunothrombosis may be a possible cause of atrial remodeling, and therefore be an underlying cause of AF.
METHODS
METHODS
From 1990 to 2014, we followed participants aged 55 and over, free from AF at inclusion. Immunothrombosis factors fibrinogen, von Willebrand factor, ADAMTS13, and neutrophil extracellular traps (NETs) levels were measured at baseline. Participants were followed until either onset of AF, loss-to-follow-up, or reaching the end-date of 01-01-2014. Cox proportional hazard modelling was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for cardiovascular risk factors.
RESULTS
RESULTS
We followed 6174 participants (mean age 69.1 years, 57% women) for a median follow-up time of 12.8 years. 364 men (13.7%, incidence rate 13.0/1000 person-years) and 365 women (10.4%, incidence rate 8.9/1000 person-years) developed AF. We found no significant association between markers of immunothrombosis and new-onset AF after adjusting for cardiovascular risk factors [HR 1.00 (95% CI 0.93-1.08) for fibrinogen, 1.04 (0.97-1.12) for von Willebrand factor, 1.00 (1.00-1.01) for ADAMTS13, and 1.01 (0.94-1.09) for NETs]. In addition, we found no differences in associations between men and women.
CONCLUSION
CONCLUSIONS
We found no associations between markers of immunothrombosis and new-onset AF in the general population. Inflammation and immunothrombosis may be associated with AF through other cardiovascular risk factors or predisposing conditions of AF. Our findings challenge the added value of biomarkers in AF risk prediction.
Identifiants
pubmed: 34559294
doi: 10.1007/s00392-021-01938-4
pii: 10.1007/s00392-021-01938-4
pmc: PMC8766396
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-104Subventions
Organisme : Erasmus Universitair Medisch Centrum Rotterdam
ID : MRace grant
Organisme : CSL Behring
ID : Prof. Heimburger Award 2018
Organisme : Hartstichting
ID : 2012T008
Organisme : KWF Kankerbestrijding
ID : NKI-20157737
Organisme : ZonMw
ID : Gender
Pays : Netherlands
Organisme : ZonMw
ID : Prevention grant (555003017)
Pays : Netherlands
Informations de copyright
© 2021. The Author(s).
Références
J Am Coll Cardiol. 2012 Dec 4;60(22):2263-70
pubmed: 23194937
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Curr Cardiol Rev. 2019;15(2):136-144
pubmed: 30516110
Hypertension. 2007 Apr;49(4):748-60
pubmed: 17309954
J Am Coll Cardiol. 2007 Nov 20;50(21):2021-8
pubmed: 18021867
Circulation. 2003 Dec 16;108(24):3006-10
pubmed: 14623805
Blood. 2015 Dec 17;126(25):2739-46
pubmed: 26511134
Nat Med. 2017 Mar 7;23(3):279-287
pubmed: 28267716
J Arrhythm. 2018 Jun 04;34(4):394-401
pubmed: 30167010
Eur J Epidemiol. 2011 Jun;26(6):449-55
pubmed: 21424216
Med Sci Monit. 2003 Sep;9(9):RA225-9
pubmed: 12960937
J Mol Cell Cardiol. 2011 Oct;51(4):600-6
pubmed: 21059352
J Thromb Haemost. 2012 Jul;10(7):1439-42
pubmed: 22507459
Eur J Epidemiol. 2020 May;35(5):483-517
pubmed: 32367290
Science. 2014 Dec 5;346(6214):1234-8
pubmed: 25477463
Int J Cardiol. 2012 Mar 8;155(2):217-22
pubmed: 20965585
Thromb Haemost. 2020 Aug;120(8):1200-1207
pubmed: 32506417
J Interv Card Electrophysiol. 2009 Jun;25(1):9-18
pubmed: 19280327
Circulation. 2010 Jan 19;121(2):200-7
pubmed: 20048208
Semin Immunol. 2016 Dec;28(6):561-569
pubmed: 27866916
Thromb Haemost. 2019 Dec;119(12):1901-1919
pubmed: 31499565
PLoS One. 2021 Apr 22;16(4):e0250265
pubmed: 33886636
Eur Heart J. 2010 Jul;31(14):1730-6
pubmed: 20501475
Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1359-62
pubmed: 9743222
Circulation. 2006 Aug 15;114(7):e257-354
pubmed: 16908781
Heart Rhythm. 2011 Apr;8(4):583-9
pubmed: 21118728
Int J Cardiol. 2013 Sep 20;168(1):317-25
pubmed: 23041092
J Am Heart Assoc. 2019 Mar 19;8(6):e010976
pubmed: 30841775
J Thromb Haemost. 2011 Jul;9(7):1415-7
pubmed: 21518247
Hematol Oncol Clin North Am. 2007 Aug;21(4):609-32, v
pubmed: 17666281
Circulation. 1976 Feb;53(2):273-9
pubmed: 128423
Mediators Inflamm. 2017;2017:5620314
pubmed: 28634421
Europace. 2018 Oct 1;20(10):1565-1565ao
pubmed: 29961863
Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1977-84
pubmed: 25012129
Compr Physiol. 2015 Apr;5(2):649-65
pubmed: 25880508
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
J Clin Invest. 2011 Aug;121(8):2955-68
pubmed: 21804195
Br J Haematol. 2005 Apr;129(1):93-100
pubmed: 15801961
Circulation. 1997 Aug 19;96(4):1180-4
pubmed: 9286947
Surgery. 2005 Aug;138(2):275-82
pubmed: 16153437
Nat Immunol. 2001 Sep;2(9):777-80
pubmed: 11526384
Eur Heart J. 2006 Apr;27(8):949-53
pubmed: 16527828
Eur Heart J. 2017 Jun 7;38(22):1717-1727
pubmed: 27252448
JAMA. 1987 Sep 4;258(9):1183-6
pubmed: 3626001
Heart Rhythm. 2017 Dec;14(12):1849-1855
pubmed: 28757307
Eur Heart J. 2014 Jun 7;35(22):1457-65
pubmed: 24302269
Am J Cardiol. 2006 Jul 1;98(1):75-81
pubmed: 16784925
J Thromb Haemost. 2015 Jun;13 Suppl 1:S82-91
pubmed: 26149054
Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):2032-2040
pubmed: 23818485
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
Nat Rev Cardiol. 2015 Apr;12(4):230-43
pubmed: 25622848
Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32
pubmed: 15198963
Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2446-2451
pubmed: 27737864